Biomarin Pharmaceutical Inc (NASDAQ:BMRN)
| 78.15 Delayed Data As of 4:00pm ET |  +0.77 / +1.00%Today’s Change | 71.65 Today|||52-Week Range 92.57 | -10.88% Year-to-Date |
Latest BMRN News | Press Releases
| Biotech Stock Roundup: MRNA Submits Vaccine Data, BMRN Down on Clinical Hold & More Sep 08 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 77.38 |
| Today’s open | 77.54 |
| Day’s range | 77.54 - 78.84 |
| Volume | 38,155 |
| Average volume (3 months) | 1,057,397 |
| Market cap | $14.3B |
Data as of 4:00pm ET, 09/21/2021
Growth & Valuation
| Earnings growth (last year) | -- |
| Earnings growth (this year) | -110.71% |
| Earnings growth (next 5 years) | +51.10% |
| Revenue growth (last year) | +9.25% |
| P/E ratio | 17.7 |
| Price/Sales | 9.12 |
| Price/Book | 3.44 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| ZLABZai Lab Ltd | -4.92 | -3.97% |
| NVAXNovavax Inc | +2.23 | +0.98% |
| NTLAIntellia Therapeutic... | -0.82 | -0.55% |
| EXASExact Sciences Corp | +0.43 | +0.41% |
Data as of 5:57pm ET, 09/21/2021
Financials
| Next reporting date | October 28, 2021 |
| EPS forecast (this quarter) | -$0.24 |
| Annual revenue (last year) | $1.8B |
| Annual profit (last year) | $859.1M |
| Net profit margin | 46.63% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters San Rafael, California |
Forecasts
